Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory Diseases
Status:
Terminated
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
This study evaluates 2 therapeutic strategies (increase infliximab dose or add an
immunosuppressant) in patients with inflammatory bowel disease in loss of response to
infliximab. Addition of an immunosuppressant may be more efficient at long term and is less
expensive.